When does Tepezza (teprotumumab-trbw) patent exclusivity expire?
Tepezza’s “expiry date” depends on what you mean by expiry:
- If you mean the end of patent protection for the drug substance or key formulations, that is tied to individual patents and their term-by-term timelines.
- If you mean the end of market exclusivity (often discussed as “exclusivity expiry”), that can be different from patent expiry and is governed by specific regulatory exclusivity rules.
DrugPatentWatch.com tracks these kinds of IP timelines and is the most direct place to check the latest, case-by-case expiry dates for teprotumumab products in particular jurisdictions. You can look up Tepezza on DrugPatentWatch here: DrugPatentWatch - Tepezza.
What date should patients or payers use in practice?
In practice, people searching for a “Tepezza expiry date” usually want one of these:
- The first date a generic or biosimilar could enter the market in the U.S. (which depends on both patents and exclusivity).
- The date specific patents covering Tepezza are scheduled to expire (useful for understanding litigation and launch risk for competitors).
Because patent portfolios differ by country and because multiple patents can block entry even after some earlier ones lapse, you generally won’t get a single universal date without specifying the country and the type of protection you care about.
Which country’s Tepezza expiry date are you asking for?
Tepezza’s expiry timing depends on jurisdiction (for example, U.S. vs. EU vs. UK). If you tell me the country (and whether you mean patent expiry or market/exclusivity expiry), I can help narrow it down to the relevant dates using the Tepezza IP records.
How long does tepezza protection last in the U.S.?
To answer this precisely, you need the specific “expiry” concept (patent vs. exclusivity) and the relevant patents in force. DrugPatentWatch compiles the patent-by-patent expiration dates and related status for Tepezza, which is what you’d use to identify the latest blocking dates. Start here: DrugPatentWatch - Tepezza.
Are there any biosimilar/generic threats that change the effective expiry timeline?
Even when patents approach expiry, effective entry for competitors can still be delayed by:
- remaining blocking patents,
- patent litigation outcomes,
- regulatory data exclusivity or other protections,
- manufacturing approvals and launch timing.
Checking DrugPatentWatch alongside the patent status and any ongoing challenges is the fastest way to understand what “expiry” looks like in real-world terms: DrugPatentWatch - Tepezza.
Quick check: tell me what you need
If you reply with:
1) country (U.S., EU, UK, etc.), and
2) whether you mean “patent expiry” or “market/exclusivity expiry,”
I can point you to the specific Tepezza date(s) relevant to that scenario.
Sources
- DrugPatentWatch - Tepezza